Gossamer Bio, Inc. Common Stock
Here’s whether Gossamer Bio, Inc. Common Stock (GOSS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-3.91% over 10 days); RSI 27 — oversold; weak 1-year return of -92.1%; 3-month momentum negative (-54.6%). Currently 96.0% off its 52-week high. Score: -7/7.
GOSS is trading below its 200-day MA ($1.28) — a key warning sign the longer-term trend is under pressure. An RSI of 26.6 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -92.1% compares to +20.4% for SPY (trailed the market by 112.5%). The current 96.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.